Psychometric testing of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) subscale in a longitudinal study of cancer patients treated with chemotherapy.
Chemotherapy
Confirmatory factor analysis
EORTC QLQ-CIPN20
FACT/GOG-Ntx
Peripheral neuropathy
Psychometrics
Responsiveness
Journal
Health and quality of life outcomes
ISSN: 1477-7525
Titre abrégé: Health Qual Life Outcomes
Pays: England
ID NLM: 101153626
Informations de publication
Date de publication:
23 Jul 2020
23 Jul 2020
Historique:
received:
14
12
2018
accepted:
10
07
2020
entrez:
25
7
2020
pubmed:
25
7
2020
medline:
22
10
2020
Statut:
epublish
Résumé
The aim of this study was to evaluate the psychometric properties of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) subscale in a longitudinal study of cancer patients treated with chemotherapy. Patients were assessed with the FACT/GOG-Ntx subscale, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chemotherapy-Induced Peripheral Neuropathy Scale 20 (EORTC QLQ-CIPN20), National Cancer Institute -Common Terminology Criteria for Adverse Events (NCI-CTCAE), and light touch test using 10 g monofilament for up to ten assessment points from baseline (prior to initiation of first chemotherapy), after the end of each cycle (up to 6 cycles, 3 weeks per cycle), and at 6, 9, and 12 months after starting chemotherapy. Psychometric analyses included internal consistency reliability, convergent validity, factorial validity, sensitivity to change and responsiveness (minimal clinically important difference, MCID). Cronbach's alpha coefficients of the FACT/GOG-Ntx subscale were 0.82-0.89 across assessment points. The subscale strongly correlated with the EORTC QLQ-CIPN20 (r = 0.79-0.93) but low-to-moderately correlated with the NCI-CTCAE sensory (r The FACT/GOG-Ntx subscale has satisfactory reliability, validity, sensitivity to change and responsiveness to evaluate CIPN in cancer patients. Future research is needed to explore the factorial structure of the FACT/GOG-Ntx subscale as the published four-factor structure was not supported in this study.
Sections du résumé
BACKGROUND
BACKGROUND
The aim of this study was to evaluate the psychometric properties of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) subscale in a longitudinal study of cancer patients treated with chemotherapy.
METHODS
METHODS
Patients were assessed with the FACT/GOG-Ntx subscale, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chemotherapy-Induced Peripheral Neuropathy Scale 20 (EORTC QLQ-CIPN20), National Cancer Institute -Common Terminology Criteria for Adverse Events (NCI-CTCAE), and light touch test using 10 g monofilament for up to ten assessment points from baseline (prior to initiation of first chemotherapy), after the end of each cycle (up to 6 cycles, 3 weeks per cycle), and at 6, 9, and 12 months after starting chemotherapy. Psychometric analyses included internal consistency reliability, convergent validity, factorial validity, sensitivity to change and responsiveness (minimal clinically important difference, MCID).
RESULTS
RESULTS
Cronbach's alpha coefficients of the FACT/GOG-Ntx subscale were 0.82-0.89 across assessment points. The subscale strongly correlated with the EORTC QLQ-CIPN20 (r = 0.79-0.93) but low-to-moderately correlated with the NCI-CTCAE sensory (r
CONCLUSION
CONCLUSIONS
The FACT/GOG-Ntx subscale has satisfactory reliability, validity, sensitivity to change and responsiveness to evaluate CIPN in cancer patients. Future research is needed to explore the factorial structure of the FACT/GOG-Ntx subscale as the published four-factor structure was not supported in this study.
Identifiants
pubmed: 32703223
doi: 10.1186/s12955-020-01493-y
pii: 10.1186/s12955-020-01493-y
pmc: PMC7376939
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Observational Study
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
246Subventions
Organisme : School of Nursing, The Hong Kong Polytechnic University
ID : No
Références
Ann Neurol. 2017 Jun;81(6):772-781
pubmed: 28486769
Int J Gynecol Cancer. 2003 Nov-Dec;13(6):741-8
pubmed: 14675309
Cancer Nurs. 2019 May/Jun;42(3):179-189
pubmed: 29649081
Qual Life Res. 2017 Nov;26(11):2999-3010
pubmed: 28634676
J Clin Oncol. 2014 Jun 20;32(18):1941-67
pubmed: 24733808
J Clin Oncol. 2016 Aug 10;34(23):2712-20
pubmed: 27354478
Curr Oncol. 2014 Aug;21(4):174-80
pubmed: 25089099
Support Care Cancer. 2014 Aug;22(8):2261-9
pubmed: 24789421
Support Care Cancer. 2013 Jul;21(7):2059-66
pubmed: 23446880
Ann Oncol. 2013 Feb;24(2):454-62
pubmed: 22910842
Pain. 2014 Dec;155(12):2461-70
pubmed: 25261162
Cancer Control. 2018 Jan-Mar;25(1):1073274818756608
pubmed: 29480026
Cancer. 2003 Aug 15;98(4):822-31
pubmed: 12910528
J Peripher Nerv Syst. 2010 Dec;15(4):314-25
pubmed: 21199103
Support Care Cancer. 2009 Dec;17(12):1483-91
pubmed: 19330359
Cancer Sci. 2016 Oct;107(10):1453-1457
pubmed: 27412083
Support Care Cancer. 2014 Oct;22(10):2767-73
pubmed: 24811218
Health Qual Life Outcomes. 2005 Apr 05;3:23
pubmed: 15811176
Health Qual Life Outcomes. 2018 Dec 11;16(1):228
pubmed: 30537955
Asia Pac J Clin Oncol. 2019 Feb;15(1):56-62
pubmed: 29873180
J Clin Epidemiol. 2007 Jan;60(1):34-42
pubmed: 17161752
Eur J Cancer Care (Engl). 2017 Sep;26(5):
pubmed: 26786536
Otolaryngol Head Neck Surg. 2019 Oct;161(4):551-560
pubmed: 31159641
Eval Health Prof. 2005 Jun;28(2):172-91
pubmed: 15851772
Semin Oncol. 2006 Feb;33(1):15-49
pubmed: 16473643
Eur J Cancer. 2010 Feb;46(3):479-94
pubmed: 20045310
Int J Gynecol Cancer. 2007 Mar-Apr;17(2):387-93
pubmed: 17362317
Psychol Bull. 1992 Jul;112(1):155-9
pubmed: 19565683